HOB Biotech GroupLtd Past Earnings Performance
Past criteria checks 1/6
HOB Biotech GroupLtd's earnings have been declining at an average annual rate of -14.6%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 12.4% per year. HOB Biotech GroupLtd's return on equity is 4.4%, and it has net margins of 8.8%.
Key information
-14.6%
Earnings growth rate
-21.4%
EPS growth rate
Biotechs Industry Growth | 11.3% |
Revenue growth rate | 12.4% |
Return on equity | 4.4% |
Net Margin | 8.8% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
HOB Biotech GroupLtd's (SHSE:688656) Anemic Earnings Might Be Worse Than You Think
Nov 04HOB Biotech GroupLtd's (SHSE:688656) Earnings Are Weaker Than They Seem
May 06Recent updates
HOB Biotech Group Corp.,Ltd's (SHSE:688656) Popularity With Investors Under Threat As Stock Sinks 29%
Dec 23HOB Biotech GroupLtd's (SHSE:688656) Anemic Earnings Might Be Worse Than You Think
Nov 04Earnings Not Telling The Story For HOB Biotech Group Corp.,Ltd (SHSE:688656) After Shares Rise 43%
Oct 08Subdued Growth No Barrier To HOB Biotech Group Corp.,Ltd's (SHSE:688656) Price
Jul 04HOB Biotech GroupLtd's (SHSE:688656) Earnings Are Weaker Than They Seem
May 06Earnings Not Telling The Story For HOB Biotech Group Corp.,Ltd (SHSE:688656) After Shares Rise 25%
Mar 08Revenue & Expenses Breakdown
How HOB Biotech GroupLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 401 | 35 | 160 | 45 |
30 Jun 24 | 407 | 46 | 152 | 46 |
31 Mar 24 | 399 | 46 | 148 | 47 |
31 Dec 23 | 394 | 47 | 141 | 46 |
30 Sep 23 | 366 | 36 | 137 | 48 |
30 Jun 23 | 360 | 39 | 133 | 45 |
31 Mar 23 | 325 | 34 | 126 | 41 |
31 Dec 22 | 320 | 42 | 119 | 38 |
30 Sep 22 | 336 | 56 | 124 | 36 |
30 Jun 22 | 321 | 65 | 112 | 34 |
31 Mar 22 | 333 | 86 | 103 | 32 |
31 Dec 21 | 318 | 86 | 100 | 31 |
30 Sep 21 | 314 | 93 | 91 | 27 |
30 Jun 21 | 291 | 83 | 85 | 25 |
31 Mar 21 | 262 | 75 | 77 | 24 |
31 Dec 20 | 222 | 57 | 70 | 23 |
30 Sep 20 | 206 | 48 | 71 | 23 |
31 Dec 19 | 259 | 64 | 79 | 24 |
31 Dec 18 | 201 | 40 | 60 | 23 |
31 Dec 17 | 146 | 21 | 49 | 19 |
31 Dec 16 | 112 | 4 | 45 | 22 |
Quality Earnings: 688656 has high quality earnings.
Growing Profit Margin: 688656's current net profit margins (8.8%) are lower than last year (9.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688656's earnings have declined by 14.6% per year over the past 5 years.
Accelerating Growth: 688656's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 688656 had negative earnings growth (-1.5%) over the past year, making it difficult to compare to the Biotechs industry average (1.3%).
Return on Equity
High ROE: 688656's Return on Equity (4.4%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/25 19:54 |
End of Day Share Price | 2024/12/25 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HOB Biotech Group Corp.,Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|